Update on ophthalmic manifestations of systemic lupus erythematosus: pathogenesis and precision medicine

2021 ◽  
Vol 32 (6) ◽  
pp. 583-589
Author(s):  
Iris Lee ◽  
Lisa Zickuhr ◽  
Lynn Hassman
Lupus ◽  
2021 ◽  
pp. 096120332110503
Author(s):  
Nitish Jawahar ◽  
Jessica K Walker ◽  
Philip I Murray ◽  
Caroline Gordon ◽  
John A Reynolds

Objective Ophthalmic complications in Systemic Lupus Erythematosus (SLE) are broad and can occur in up to a third of patients. The British Isles Lupus Assessment Group (BILAG) 2004 Index identifies 13 ocular manifestations of active SLE, as opposed to those related to previous disease activity and/or the consequences of therapy. We conducted a systematic review of published literature to determine the frequency of ophthalmic manifestations of active SLE. Methods A systematic literature search of Ovid MEDLINE and EMBASE from their respective inceptions to July 2020 was conducted to identify cohort, case–control and cross-sectional studies. Results 22 studies meeting eligibility criteria were included. Most studies featured small sample sizes and were judged to have a high risk of methodological bias. The number and quality of studies did not allow us to confidently estimate the incidence of the conditions. No studies reported epidemiological data for orbital inflammation/myositis/proptosis. The prevalence of each of the other ocular manifestations, with the exception of retinal vaso-occlusive disease, was consistently less than 5%. Retinal vasculitis, uveitis and isolated cotton wool spots tended to be associated with more active SLE disease. Conclusion The prevalence of eye disease due to SLE activity is uncommon, but clinicians should be aware that some conditions tend to be associated with more active systemic disease. Further studies to determine the incidence and risk factors for these ophthalmic manifestations are needed.


Cells ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 140 ◽  
Author(s):  
Yasuo Nagafuchi ◽  
Hirofumi Shoda ◽  
Keishi Fujio

Systemic lupus erythematosus (SLE) is an autoimmune disorder with a wide range of clinical symptoms. Enormous progress has been made in the immunological and genetic understanding of SLE. However, the biology of disease heterogeneity in SLE has remained largely unexplored. Human immune profiling studies, helped by recent technological advances especially in single-cell and “omics” analyses, are now shedding light on the cellular and molecular basis of clinical symptoms and disease flares in individual patients. Peripheral blood immunophenotyping analysis with flow cytometry or mass cytometry are identifying responsible cell subsets and markers characteristic of disease heterogeneity. Transcriptome analysis is discovering molecular networks responsible for disease activity, disease subtype and future relapse. In this review, we summarize recent advances in the immune profiling analysis of SLE patients and discuss how they will be used for future precision medicine.


2014 ◽  
Vol 14 (3) ◽  
pp. 138 ◽  
Author(s):  
Sheng Yan ◽  
Lok Yan Yim ◽  
Liwei Lu ◽  
Chak Sing Lau ◽  
Vera Sau-Fong Chan

2004 ◽  
Vol 172 (10) ◽  
pp. 6476-6481 ◽  
Author(s):  
M. Nusrat Sharif ◽  
Ioannis Tassiulas ◽  
Yang Hu ◽  
Ingrid Mecklenbräuker ◽  
Alexander Tarakhovsky ◽  
...  

2020 ◽  
Vol Volume 13 ◽  
pp. 39-49 ◽  
Author(s):  
Elliott Lever ◽  
Marta R Alves ◽  
David A Isenberg

Sign in / Sign up

Export Citation Format

Share Document